...
首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Riboswitch-mediated Attenuation of Transgene Cytotoxicity Increases Adeno-associated Virus Vector Yields in HEK-293 Cells
【24h】

Riboswitch-mediated Attenuation of Transgene Cytotoxicity Increases Adeno-associated Virus Vector Yields in HEK-293 Cells

机译:核糖开关介导的转基因细胞毒性的衰减增加HEK-293细胞中的腺相关病毒载体产量。

获取原文
获取原文并翻译 | 示例
           

摘要

Cytotoxicity of transgenes carried by adeno-associated virus (AAV) vectors might be desired, for instance, in oncolytic virotherapy or occur unexpectedly in exploratory research when studying sparsely characterized genes. To date, most AAV-based studies use constitutively active promoters (e. g., the CMV promoter) to drive transgene expression, which often hampers efficient AAV production due to cytotoxic, antiproliferative, or unknown transgene effects interfering with producer cell performance. Therefore, we explored artificial riboswitches as novel tools to control transgene expression during AAV production in mammalian cells. Our results demonstrate that the guanine-responsive GuaM8HDV aptazyme efficiently attenuates transgene expression and associated detrimental effects, thereby boosting AAV vector yields up to 23-fold after a single addition of guanine. Importantly, riboswitch-harboring vectors preserved their ability to express functional transgene at high levels in the absence of ligand, as demonstrated in a mouse model of AAV-TGF beta 1-induced pulmonary fibrosis. Thus, our study provides the first application-ready biotechnological system-based on aptazymes, which should enable high viral vector yields largely independent of the transgene used. Moreover, the RNA-intrinsic, small-molecule regulatable mode of action of riboswitches provides key advantages over conventional transcription factor-based regulatory systems. Therefore, such riboswitch vectors might be ultimately applied to temporally control therapeutic transgene expression in vivo.
机译:腺相关病毒(AAV)载体携带的转基因的细胞毒性可能是理想的,例如在溶瘤病毒疗法中,或在研究稀疏特征基因时在探索性研究中意外发生。迄今为止,大多数基于AAV的研究使用组成性活性启动子(例如,CMV启动子)来驱动转基因表达,由于细胞毒性,抗增殖或未知的转基因效应干扰生产细胞的性能,常常阻碍有效的AAV产生。因此,我们探索了人工核糖开关作为控制AAV在哺乳动物细胞中生产过程中转基因表达的新型工具。我们的结果表明,鸟嘌呤应答性GuaM8HDV适体酶有效地减弱了转基因表达和相关的有害作用,从而在单次添加鸟嘌呤后将AAV载体的产量提高了23倍。重要的是,如AAV-TGFβ1诱导的肺纤维化小鼠模型所示,携带核糖开关的载体在不存在配体的情况下仍能保持高水平表达功能性转基因的能力。因此,我们的研究提供了第一个基于aptazyme的可随时用于生物技术的应用系统,该系统应能使病毒载体的产量大大提高,而与所使用的转基因无关。而且,核糖开关的RNA固有的,小分子可调节的作用方式比传统的基于转录因子的调节系统具有关键优势。因此,这种核糖开关载体可以最终应用于体内时间控制治疗性转基因表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号